KOM-PAX1 : A Phase 2, open-label study of orally administered PAX-1 in combination with standard of care treatment in patients with newly diagnosed or recurrent glioblastoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18-70Age 18-70

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal
Cancers

Systemic therapy | Brain and spinal cordGlioblastoma (GBM)

Trial Overview Read MoreRead more

This Phase II trial is trying to understand the effectiveness of an oral drug (PAX-1) in combination with standard of care treatment in people with newly diagnosed or recurrent glioblastoma.
 

This trial is treating patients with glioblastoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2, open-label study of orally administered PAX-1 in combination with standard of care treatment in patients with newly diagnosed or recurrent glioblastoma

Commercial Sponsor

Novotech (Australia) Pty Limited

Summary

This is a non-randomised trial with two experimental arms. Arm 1 will consistent of people with newly diagnosed glioblastoma, and Arm 2 will consist of people with recurrent glioblastoma. Participants will receive a daily 15mg oral dose of PAX-1 (Sodium meta-arsenite) in combination with investigator choice standard of care until disease progression, patients withdraw due to tolerability, or patients withdraw consent.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Genitourinary Research Study Coordinator
gu.oncresearch@monashhealth.org
0436387664

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next